

NYRx Drug Class Coverage Overview: Proton Pump (PPI)/Acid Secretion Inhibitors

Drugs in the Proton Pump (PPI) / Acid Secretion Inhibitors drug class are included on the [NYRx Preferred Drug List \(PDL\)](#) and are subject to prior authorization (PA) requirements of the [NYRx Drug Utilization Review \(DUR\) Program](#):

Preferred Drugs	Non-Preferred Drugs	Prior Authorization/Coverage Parameters
VII. Gastrointestinal		
Proton Pump (PPI)/Acid Secretion Inhibitors F/Q/D		
esomeprazole magnesium Rx capsule lansoprazole capsule (Rx, OTC) lansoprazole OTC solutab omeprazole Rx pantoprazole tablet Protonix suspension BLTG rabeprazole	dexlansoprazole (gen Dexilant®) Dexilant® DO esomeprazole magnesium tablet OTC esomeprazole capsules OTC esomeprazole suspension esomeprazole DR packets Konvomep™ lansoprazole Rx solutab Nexium® Rx DO omeprazole OTC omeprazole/sodium bicarbonate Rx pantoprazole suspension Prevacid® OTC Prevacid® Rx DO Prilosec® Rx Protonix® tablet Voquezna®	DOSE OPTIMIZATION (DO) <ul style="list-style-type: none"> See Dose Optimization Chart for affected strengths FREQUENCY/QUANTITY/DURATION (F/Q/D) <ul style="list-style-type: none"> Quantity limits: <ul style="list-style-type: none"> Once daily dosing for: <ul style="list-style-type: none"> GERD erosive esophagitis healing and maintenance of duodenal/gastric ulcers (including NSAID-induced) prevention of NSAID-induced ulcers Twice daily dosing for: <ul style="list-style-type: none"> hypersecretory conditions Barrett's esophagitis H. pylori refractory GERD Duration limits: <ul style="list-style-type: none"> 90 days for: <ul style="list-style-type: none"> GERD 365 days for: <ul style="list-style-type: none"> Maintenance treatment of duodenal ulcers, or erosive esophagitis 14 days for: <ul style="list-style-type: none"> H. pylori

Prior Authorization Requirements

Preferred drugs will not require PA if the required coverage parameters are found in the member's Medicaid claim history and the correct Frequency/Quantity/Duration (F/Q/D) limits are met at the time of pharmacy claim submission. Non-preferred drugs in these classes require prior authorization (PA), unless indicated otherwise.

Frequency/Quantity/Duration

All drugs in this class are subject to F/Q/D limitations based on diagnosis. NYRx recognizes diagnosis by the ICD-10 code included in a member's Medicaid claim history. Providers should include all applicable

diagnosis codes in a member's EMR and submit their claims promptly to decrease the need to manually obtain PA.

Quantity Limits

Quantity limits are based on FDA labeling and/or compendia-supported use. Quantity limits include:

- Once daily dosing for:
 - GERD
 - erosive esophagitis
 - healing, and maintenance of duodenal/gastric ulcers (including NSAID-induced)
 - prevention of NSAID-induced ulcers
- Twice daily dosing for:
 - hypersecretory conditions
 - Barrett's esophagitis
 - H. pylori
 - refractory GERD

Duration Limits

Duration of treatment is based on FDA labeling and/or compendia-supported use. Duration limits include:

- 90 days for GERD
- 365 days for maintenance treatment of duodenal ulcers or erosive esophagitis
- 14 days for H. pylori

Dose Optimization

The following drugs and strengths are subject to dose optimization limits of one unit per day:

- Dexilant® 30mg capsule
- Nexium® 5mg, 10mg, 20mg packet
- Nexium® 20mg capsule
- Prevacid® DR 15mg capsule

Prior authorization will be required outside of these criteria.

Brand Less Than Generic

The following drugs are subject to the [Brand Less Than Generic \(BLTG\) Program](#):

- Protonix® suspension

Prescribers should not initiate a prior authorization for the generic equivalent of these drugs. Pharmacies should submit DAW code 9 (Substitution Allowed by Prescriber but Plan Requests Brand).

What all Providers Need to Know

Proton Pump (PPI) / Acid Secretion Inhibitors are very effective agents but are not without adverse effects, especially when used in higher daily doses or with long-term use. These agents have been associated with increased risk of clostridium difficile, bone fractures, vitamin B-12 deficiency, hypomagnesemia, fund gland polyps, and hospital- and community-acquired pneumonia. Prescribers should consider the risks and benefits of Proton Pump (PPI) / Acid Secretion Inhibitors therapy and fully inform patients of side effects before prescribing.

New York State Medicaid Prescriber Education Program

To learn more about the use of Proton Pump (PPI) / Acid Secretion Inhibitors and earn continuing education credit consider the free online Medicaid Prescriber Education Program (MPEP) article [Stewardship of Proton Pump Inhibitors: Considerations for Use and Deprescribing](#).

The Medicaid Prescriber Education Program (MPEP) is a partnership between the New York State Department of Health and the University at Buffalo School of Pharmacy. MPEP offers free online accredited continuing education on current topics in pharmacotherapy for healthcare professionals. To learn more, please visit the [New York State Medicaid Prescriber Education Program website](#) or scan the following QR code:



What Pharmacy Providers Need to Do

Pharmacy providers should become familiar with the Proton Pump (PPI) / Acid Secretion Inhibitors coverage criteria in the [PDL](#) and incorporate this information when discussing the need for PA with prescribers.

What Prescribers Need to Do

Prescribers should refer to the Proton Pump (PPI) / Acid Secretion Inhibitors coverage criteria in the [PDL](#) and incorporate this information when prescribing these drugs for Medicaid members.

Resources

- [NYRx Brand Less Than Generic Program](#)
- [NYRx Drug Utilization Review Program](#)
- [NYRx Education & Outreach Website](#)
- [NYRx Preferred Drug List](#)
- [NYRx Prior Authorization Submission Guide](#)
- [NYRx Standard Prior Authorization Request Form](#)
- [New York State Medicaid Prescriber Education Program Website](#)
- [Stewardship of Proton Pump Inhibitors: Considerations for Use and Deprescribing](#)

Contact Information

The NYRx Education & Outreach Call Center is available by phone at 1-833-967-7310 or by email at NYRxEO@primetherapeutics.com from 8:00 AM to 5:00 PM ET, Monday through Friday, excluding holidays.

The NYRx Education & Outreach team hosts virtual office hours every week for stakeholders to ask questions related to NYRx and care coordination. Visit the [NYRx Education & Outreach website](#) for more information.